We had the pleasure to talk to Maria Cinta Cid (Hospital Clinic Barcelona, Barcelona, Spain) about the use of mavrilimumab in patients with giant cell arteritis (Clinical Trial Identifier: NCT03827018). The abstract ‘Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis’ (ABSTRACT NUMBER: L06) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
- Could you tell us a little about giant cell arteritis, its prognosis and incidence? (0:05)
- What is the current standard of care for giant cell arteritis, and what are the limitations of this treatment? (1:52)
- What is the mechanism of action of mavrilimumab? (6:07)
Disclosure: Maria Cinta Cid discloses receiving consulting/advisory board fees from GSK, Abbvie and Janssen, lecturing fees from Vifor and a research grant from Kiniksa. Maria Cinta Cid was regional lead for the GiACTA trial (Riche) and co-PI for the KPL-301-C001 trial with mavrilimumab.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).
Share this Video
Related Videos In Rheumatic Diseases
Nicholas Harvey, WCO21: The Royal Osteoporosis Society Research Roadmap
touchIMMUNOLOGY joins Professor Nicholas Harvey (University of Southampton, UK) at WCO21 to discuss the aims and hopes of the Royal Osteoporosis Society’s Research Roadmap initiative. Questions 1. What are the current unmet needs in osteoporosis and bone research? (00:27-01:26) 2. Please can you provide a short summary of the main aims of the Osteoporosis and […]
Emma Clark, WCO21: Novel Technologies for Skeletal Assessment
touchIMMUNOLOGY joins Professor Emma Clark (University of Bristol, UK) at WCO21 to discuss the current limitations of osteoporosis diagnosis and the latest novel technologies for skeletal assessment. Questions 1. Why is the diagnosis of osteoporosis so challenging? (00:16-02:13) 2. What are the strengths and limitations of currently available tools and services to diagnose osteoporosis? (02:13-04:28) […]
Philip Conaghan, WCO21: Tanezumab in the Treatment of Patients with Moderate-to-severe Osteoarthritis
touchIMMUNOLOGY joins Professor Philip Conaghan (University of Leeds, UK) at WCO21 to discuss improvements in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and use of tanezumab in the treatment of patients with moderate-to-severe osteoarthritis. Questions 1. What is the rationale for the use of tanezumab in the treatment of patients with moderate-to-severe osteoarthritis? […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!